New combo therapy aims to revive immune attack on tough lung cancers
NCT ID NCT05013450
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study tests whether adding two drugs (dupilumab and anakinra) to standard immunotherapy can help shrink or control advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. About 33 adults whose cancer progressed after PD-1/PD-L1 treatment will receive the combination. The goal is to check safety and see if the tumors respond on scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tisch Cancer Institute, Mount Sinai Hospital
New York, New York, 10003, United States
Conditions
Explore the condition pages connected to this study.